Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer

Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, Hyun Cheol Chung

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purposes. We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy. Methods. A weekly infusion of gemcitabine at 850 mg/m2for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles. Results. Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2-25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group. Conclusion. Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.

Original languageEnglish
Pages (from-to)215-221
Number of pages7
JournalBreast Cancer Research and Treatment
Volume90
Issue number3
DOIs
Publication statusPublished - 2005 Apr 1

Fingerprint

gemcitabine
Breast Neoplasms
Drug Therapy
Salvage Therapy
Survival
Leukopenia
Granulocyte Colony-Stimulating Factor
Neutropenia
Thrombocytopenia
Doxorubicin
Disease Progression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Rha, Sun Young ; Moon, Yong Hwa ; Jeung, Hei Chul ; Kim, Yong Tae ; Sohn, Joo Hyuk ; Yang, Woo Ick ; Suh, Chang Ok ; Kim, Gwi Eon ; Roh, Jae Kyung ; Chung, Hyun Cheol. / Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. In: Breast Cancer Research and Treatment. 2005 ; Vol. 90, No. 3. pp. 215-221.
@article{938489fb7d494c1997e4a36e30d37afe,
title = "Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer",
abstract = "Purposes. We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy. Methods. A weekly infusion of gemcitabine at 850 mg/m2for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles. Results. Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2-25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group. Conclusion. Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.",
author = "Rha, {Sun Young} and Moon, {Yong Hwa} and Jeung, {Hei Chul} and Kim, {Yong Tae} and Sohn, {Joo Hyuk} and Yang, {Woo Ick} and Suh, {Chang Ok} and Kim, {Gwi Eon} and Roh, {Jae Kyung} and Chung, {Hyun Cheol}",
year = "2005",
month = "4",
day = "1",
doi = "10.1007/s10549-004-2468-4",
language = "English",
volume = "90",
pages = "215--221",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. / Rha, Sun Young; Moon, Yong Hwa; Jeung, Hei Chul; Kim, Yong Tae; Sohn, Joo Hyuk; Yang, Woo Ick; Suh, Chang Ok; Kim, Gwi Eon; Roh, Jae Kyung; Chung, Hyun Cheol.

In: Breast Cancer Research and Treatment, Vol. 90, No. 3, 01.04.2005, p. 215-221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer

AU - Rha, Sun Young

AU - Moon, Yong Hwa

AU - Jeung, Hei Chul

AU - Kim, Yong Tae

AU - Sohn, Joo Hyuk

AU - Yang, Woo Ick

AU - Suh, Chang Ok

AU - Kim, Gwi Eon

AU - Roh, Jae Kyung

AU - Chung, Hyun Cheol

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Purposes. We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy. Methods. A weekly infusion of gemcitabine at 850 mg/m2for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles. Results. Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2-25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group. Conclusion. Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.

AB - Purposes. We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy. Methods. A weekly infusion of gemcitabine at 850 mg/m2for 30 min, for 3 of every 4 weeks, was introduced in advanced breast cancer patients who had failed previous doxorubicin and taxane based chemotherapy. There was no dose modification, and the treatment was delayed until the leukopenia was recovered with G-CSF support. The efficacy was evaluated every three cycles and the treatment was continued until either disease progression or 12 cycles. Results. Of 41 enrolled patients, 38 were evaluable with a median age of 47. Total 178 cycles of gemcitabine was administered and the relative dose intensity was 89. The toxicity was mild with 12 of grade III neutropenia and 14 of grade III/IV thrombocytopenia without clinical symptoms. The response rate was 20 (8/38), comprising two complete and six partial responses. The median response duration and overall survival were 9 (2-25) and 11 months, respectively. The overall survival of 12 months was better in the third line patients than the 7 months in the fourth line treatment group. Conclusion. Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=20244369445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244369445&partnerID=8YFLogxK

U2 - 10.1007/s10549-004-2468-4

DO - 10.1007/s10549-004-2468-4

M3 - Article

C2 - 15830134

AN - SCOPUS:20244369445

VL - 90

SP - 215

EP - 221

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -